

## B C P – Statement (Business Continuity Planning)

Product group: MCC, Starch, Lactose,  
Inhalation, Biopharma  
and Superdisintegrants

All products manufactured by:  
DFE Pharma GmbH & Co. KG

Document No.: PD-0296 Page 1 of 1

Dear Customer,

Herewith we confirm that Business Continuity Planning is a vital activity for DFE Pharma GmbH & Co. KG. Our activities in this field of responsibility start with considering the impact of a potential disaster (e.g. force majeure risk, pandemic outbreak) as well as understanding the underlying risks.


Based on this DFE Pharma is actively identifying the essential business functions and assessing the disaster risks that could adversely affect our business continuity.

DFE Pharma has systems in place to guarantee good communication with our customers should such a disaster cause a change to DFE Pharma normal business practice. It is our base principle to endeavor to maintain supply to our customers by rapid implementation of the necessary actions plans for incident management and disaster recovery.

This statement substitutes all previous versions issued for the brand names mentioned above. We trust this information, which is made up to the best of our knowledge, will be helpful to you.

**Name** : Wilbert van de Rakt

**Job title** : Quality Director

**Signature** : 

This document is controlled by a validated, electronic system and is valid without signature.  
The above facsimile signature is only for display.